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Modern antiretroviral therapies can confer effective suppression of HIV-1 infection. However, 
HIV-infected people discontinuing antiretroviral therapy experience a rebound of virus from a 
persistent reservoir. Characterizing this reservoir constitutes a crucial step towards developing a 
cure, and we hypothesized that assessing the diversity and tropism of rebound virus would 
provide insight into the types of cells that likely house the viral reservoir as well as reservoir 
diversity. We examined 10 rebound samples from a project within the large-scale AIDS Clinical 
Trials Group and used single genome amplification and Primer ID deep sequencing to assess the 
genetic diversity of the env gene, which encodes the HIV-1 envelope protein, among rebounding 
virus. Samples from the same patients with viral suppression due to antiretroviral therapy were 
also available. Most rebound virus populations showed significant diversity. All env genes 
examined were isoforms that would require cells to express high surface levels of the CD4 
receptor for entry, consistent with the current hypothesis that virus is selectively replicated in 
CD4+ T cells. These results indicate that most people discontinuing therapy release a diverse 
population of virus, and this released virus targets CD4+ T cells rather than myeloid cells, which 
tend to last longer. Research indicates that a small proportion of viruses have evolved to 
efficiently enter myeloid cells. Current HIV-1 cure strategies focus on reactivating latent HIV-1 
and targeting the resultant virus. It is essential to understand the features of rebound viruses 




HIV-1 causes approximately 6,300 new infections daily. Successful antiretroviral therapy 
(ART) reduces HIV-1 viral load in the blood down to stable low levels; however ART does not 
eliminate virus. Developing a cure for HIV-1 constitutes one of the top priorities in the HIV-1 
research field today, and such a treatment has the potential to end the dependency on ART that 
thousands currently have.  
Since ART does not fully eliminate HIV-1 infection, most people discontinuing therapy 
experience a rebound of virus from a persistent reservoir [1-4]. The variable timing of rebound, 
where the virus is coming from, and the complexity of the rebound virus are poorly understood. 
One potential source of virus is latently infected resting CD4+ T cells. These immune 
cells are well-established targets of HIV-1 infection. There is also a continual production of virus 
at low levels in spite of ART, and other cell types could be the source of rebound virus. This 
includes myeloid cells, which are differentiated from the bone marrow and can perform immune 
functions. In a largely quiescent reservoir, the rebound virus could be clonal as the result of virus 
from a single cell leaving a latent state. However, the number/complexity of the rebound virus 
within a person has recently been predicted to be much higher than predicted based on a largely 
quiescent reservoir [4]. 
To this end we have examined peripheral blood samples from ACTG study A5068 [5] to 
investigate the diversity and entry phenotype of rebound virus.  Subjects in A5068 discontinued 
ART as part of an analytic treatment interruption (ATI) and had virologic rebound detectable in 
the blood on average between 2-4 weeks after discontinuation of therapy. To study the 
complexity of the rebound virus we assessed the genetic diversity of the viral env gene and also 
examined viral entry phenotype. Phylogenetic analysis showed a high degree of diversity in the 
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rebound virus population. In addition, all Env proteins examined required high levels of CD4 for 
efficient entry, consistent with prior selection for replication in CD4+ T cells. Our analysis 
suggests that a viral population replicating in myeloid cells is not a significant source of rebound 





The AIDS Clinical Trails Group (ACTG) study A5068 examined whether structured 
treatment interruptions and/or vaccination with an exogenous HIV vaccine that consisted of an 
ALVAC-HIV vector was associated with control of viral replication during a subsequent 
analytical treatment interruption. This study included a control group with no vaccination or 
structured interruption control for comparison (Arm A). The study showed a modest effect in 
reduced peak and set point viral load of the rebound virus in the arms that included the structured 
treatment interruptions [5]. Subjects with the analytical treatment interruption only (Arm A) had 
a median CD4+ T cell count of 779 copies/mL, and viral RNA levels of less than 50 copies/mL 
at entry into the study while still on therapy. For our study, we used blood plasma samples from 
10 of these subjects early after the initiation of the analytical treatment interruption when viral 
load was at or above 1,000 copies/mL (Figure 6). A pre-therapy sample was also available for 
one subject. 
Single Genome Amplification 
Sequences of virion RNA were examined using single genome amplification (SGA) [6] 
of the full-length env gene. SGA aims to isolate cDNA specific to a single virion, allowing 
researchers to obtain individual sequences corresponding to single virions within a patient 
sample.  
Prior to HIV-1 RNA isolation from blood plasma using the QIAmp Viral RNA Mini Kit 
(Qiagen), samples were pelleted by centrifugation at 25,000 xg for 2 hours at 4 ºC. Isolated 
vRNA was reverse transcribed using Superscript III Reverse transcriptase (Invitrogen) and an 
oligo-d(T) primer. SGA was accomplished by endpoint dilutions and semi-nested PCR using 
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Platinum Taq High Fidelity polymerase (Invitrogen) and primers B3F3 (5′-
TGGAAAGGTGAAGGG GCAGTAGTAATAC-3′) LTR DN (5′-
GACTCTCGAGAAGCACTCAAGGCAAGCTTTATTGAG-3′) and B5957 UP1 (5′-
GATCAAGCTTTAGGCATCTCCTATGGCAGGAAGAAG-3′) and LTR DN for round one 
and two of PCR, respectively. Sequencing of individual PCR amplified env amplicons was 
performed, and it was confirmed that no double peaks were present in the sequencing output 
prior to phylogenetic analysis (as this would have indicated the simultaneous detection of more 
than one viral sequence).  
Next Generation Sequencing using Primer ID 
 Sequences of virion RNA were further examined using deep sequencing with Primer ID 
[7] of the V1-V3 region of the env gene. Primer ID uses unique barcodes to tag each DNA 
template during the PCR process [7]. This allows investigators to validate the number of 
templates initially present in addition to lowering the sequencing error rate to 1 in 10,000 bases 
[7]. 
We used the previously described protocol to construct Primer ID sequencing libraries 
from viral RNA. [7] In brief, the cDNA primer with a block of 9 degenerate nucleotides (Primer 
ID) was used to tag each viral template with a unique Primer ID. After purification of cDNA 
using magnetic beads, we used two rounds of PCR to amplify Primer ID tagged cDNA and to 
add Illumina barcoded adaptor sequences for multiplexing. We used MiSeq 300 bp pair-end 
platform to sequence the constructed library. Raw sequencing reads were initially de-multiplexed 
by the Illumina pipeline. We used the previously described in-house pipeline to retrieve template 
consensus sequences [7]. 
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Determination of Major Lineages  
The minimum number of rebound viruses was estimated by analyzing distinct sequence 
lineages using both the phylogenetic tree analysis and highlighter plots (Figures 1D, 2A, 3, 4) of 
each subject. Both distinct lineages and complex clusters of linked sequence differences were 
used. This means that we initially counted major clusters on the phylogenetic trees, and we then 
used the highlighter plot to analyze the diversity of different regions (5 in total of about 600 
basepairs per region) of the env gene and to counting clusters of similarly mutated regions. The 
lowest number of lineages was chosen. This was all done to avoid interpreting complexity that 
could have been the result of post-rebound recombination. These values are minimum estimates, 
as we took the lowest number of lineages counted per subject of the rebound virus complexity.  
Virus Characterization 
 Phylogenetic analysis of the full-length env genes was used to select a representative 
sampling of amplicons for cloning to assess viral entry phenotype. env genes cloned in an 
expression vector were used in cotransfection with the pNL4-3.LucR-E reporter backbone 
plasmid into 293T cells to generate an Env-pseudotyped luciferase reporter virus as described 
previously [8-10]. By comparing the ability of the pseudotyped virus to infect Affinofile cells 
expressing high versus low levels of surface CD4, we are able to consistently assess viral CD4 
entry phenotype. This allows an assignment of viral entry tropism as being largely restricted to 
CD4+ T cells when requiring high levels of CD4 for entry (T cell-tropic) versus being able to 
efficiently infect cells with a low density of CD4, as is found on macrophages (macrophage-
tropic) [8].  Sensitivity to soluble CD4 was used to confirm the CD4 entry phenotype. 




We analyzed eleven plasma samples from ten subjects (subject 43656 had a pre-therapy 
(R0) and rebound (R1) sample available; Figure 1A). We used plasma from the first available 
time point with a viral load above 1,000 copies/mL to focus on the early rebound virus. Most 
samples had viral loads less than 10,000 copies/mL (Figure 1B). Eight of ten subjects had nadir 
CD4+ T cell counts prior to therapy recorded as between 201-500 cells/mL, while one (sample 
R10) was <201 cells/mL. 
In order to determine the viral sequence diversity of the rebound samples, we employed 
deep sequencing using Primer ID to sequence the V1-V3 region of the env gene (Figure 1D), in 
addition to doing SGA of the full length env gene. Deep sequencing results were achieved for 
eight of ten rebound samples and the pre-therapy sample (however, the matching rebound sample 
R1 was unsuccessful). We estimated the minimum number of rebound viruses as distinct 
sequence lineages in the phylogenetic tree analysis and highlighter plots (Figures 1D, 2A, 3, 4). 
We used both distinct lineages and complex clusters of linked sequence differences in forming 
this estimate while trying to avoid interpreting complexity that could have been the result of 
post-rebound recombination. We consider these values as minimum estimates of the rebound 
virus complexity since the viruses considered as potential recombinants could have pre-existed in 
the reservoir and been independently reactivated. Analysis of the minimum number of lineages 
versus time (in weeks) to rebound demonstrated no obvious correlation between time to rebound 
and complexity of the rebound virus population (Figure 1C).  For virus that rebounded in the first 
few weeks we estimated between 1 and 5 distinct lineages by deep sequencing, with a mean of 
3.1 lineages, for these early rebound viruses. R2 took the longest to rebound (10 weeks) and 
showed relatively low diversity with only 2 lineages. SGA results of full length env genes 
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showed between 1 and 4 distinct lineages, with a mean of 3.1 lineages, which is similar to the 
results obtained with deep sequencing (Figure 1C). The mean intrapatient diversity was also 
determined by pairwise analysis using full-length env and ranged from 0.2% to 3.1%. Additional 
analyses of subjects early in infection (10 subjects) [11] and chronically infected subjects (7 
subjects, unpublished observation) were also done and ranged between 0.16% to 1.2% for early 
infection subjects and 1.1% to 4.1% for chronically infected subjects not on therapy. These 
numbers suggest that the rebound virus is more similar to virus in chronically infected subjects 
where multiple viral lineages form a genetically complex population. 
         We subsequently cloned individual env genes (51 total; average 4 amplicons per subject) 
from the major lineages in each participant to determine the entry phenotype of the rebound virus 
using the Affinofile cell line (Figures 2A, 4). The pre-therapy sample (R0) was also included; no 
clones were obtained for sample R5. Affinofile cells allow controlled expression of CD4 and are 
currently the most consistent method to assess CD4-dependent entry phenotype [8]. Entry 
phenotype was evaluated based on the ability of viruses pseudotyped with the Env proteins from 
the rebound virus to infect Affinofile cells expressing either high or low levels of surface CD4. 
The phenotype was confirmed by sensitivity to inhibition by soluble CD4 at a concentration of 
5.0 µg/mL when infecting TZM-bl cells [12], a level of soluble CD4 that neutralizes 
macrophage-tropic viruses but not R5 T cell-tropic viruses. None of the Env proteins tested 
showed any ability to infect cells expressing low levels of CD4 compared to their infectivity on 
cells expressing high levels of CD4 as all exhibited less than 2% relative infectivity (Figure 2B). 
All Env proteins tested were also resistant to inhibition by soluble CD4 (Figure 2D). In addition, 
the CCR5 antagonist Maraviroc inhibited all pseudotyped viruses. Therefore, all isolated Env 
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proteins used CCR5 as the coreceptor. Taken together, all Env proteins tested from the rebound 




In this report we describe entry phenotype and population complexity of the initial virus 
that rebounds from the latent or low-level viremia reservoir after therapy discontinuation. These 
features are relevant to developing strategies of HIV-1 eradication because they are features of 
the first virus that must be targeted. We evaluated entry phenotype in order to determine what 
cell type this virus had been predominantly replicating in at the time therapy was initiated and/or 
when the virus entered the latent reservoir. In addition, we examined the complexity of the 
rebound population as a measure of the minimum number of viruses that rebound from the 
reservoir and can be detected in the blood. The genetic diversity of the viral reservoir and 
rebound virus has been debated, but it is perceived to have low diversity and to be primarily 
clonal or multiclonal [13, 14].  Our results are consistent with the observation of Rothenberger et 
al.[4] who proposed a multifocal model of virus reactivation. We observed a mean of 3.1 distinct 
lineages when counting major lineages with both deep sequencing and SGA. This points to a 
minimum of 3 viruses rebounding within a short period after treatment interruption. While this is 
significantly less than the 5-25 rebound/founder viruses suggested by Rothenberger et al. [4], 
when we reanalyzed the sequence data from that study for the 3 subjects with SGA of virion 
RNA using the same criteria as used in this report, we found the mean number of distinct 
lineages to be 3.3. This is similar to what we observed. However, since we did not count 
potential recombinants in our analysis, this is a minimum estimate. 
The number of rebound viruses could be affected by factors that affect viral reservoir 
size, such as duration of ART and time after infection of ART initiation. These data are not 
available for the subjects included in this report. Reservoir size, as measured by cell-associated 
viral RNA and DNA, has been shown to be correlated with set point after therapy 
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discontinuation [15]. Sample R2 did show one of the lowest sequence diversities (0.59%) and 
took the longest to have a measurable rebound virus population, but we only analyzed one 
subject who took longer than four weeks for rebound to be detected.  
The use of viral outgrowth assays from subjects on therapy after isolation of resting 
CD4+ T cells and reactivation in culture has established this cell type as a reservoir for HIV-1 
latency [1-3]. We sought to evaluate the rebound virus population by using entry phenotype. 
Distinct lineages of HIV-1 can evolve the ability to use low levels of CD4 for entry, but these 
have been found primarily in the cerebral spinal fluid [8,11]; presumably, this localized 
evolution is due to selective pressure to enhance replication in cells such as macrophages, which 
express low levels of CD4. Here, we assessed the CD4 entry phenotype in conjunction with 
soluble CD4 sensitivity (a feature of low CD4-using Envs) to determine that the rebound viruses 
needed high levels of CD4 for efficient entry (Figure 2B). Sensitivity to inhibition by Maraviroc 
of all Env proteins showed that all of the viruses were CCR5-using (Figure 2C), making these 
viruses R5 T cell-tropic. Based on this phenotypic characterization, we can conclude that the 
rebound virus was adapted to replicating in CD4+ T cells at the time the reservoir was formed. 
These results do not define the cell type that harbored the latent virus prior to rebound (T cells or 
macrophages); however, these results exclude the possibility that the rebound virus was 
replicating extensively in a myeloid cell lineage prior to latency since this would have selected 
for the ability to use low levels of CD4 for entry. It should be noted that viral rebound in isolated 
compartments of the body, such as the brain, or viruses released later from smaller reservoirs, 
could have phenotypes that are distinct from the initial rebound virus that predominates in the 
blood. 
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In summary, we have shown that the early rebounding virus is more genetically diverse 
than previously thought. Additionally, we were able to show that all virus isolates from the 
plasma used the CCR5 co-receptor in the cell entry process and required high levels of CD4 for 
entry. Therefore, these virus isolates are R5 T cell-tropic. This excludes a population of virus 
replicating in myeloid cells as a significant contributor to the viral reservoir that repopulates 
blood early after therapy discontinuation. Elucidating the nature of this viral reservoir constitutes 
a crucial prerequisite to eliminating the latent reservoir, which will be required in order to cure 
HIV. By providing considerable insight into the genetic diversity of rebounding virus 
populations in addition to characterizing the tropism phenotypes of this virus, our findings also 
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C. Minimum Number of Viral Lineages vs. Time to Rebound
B. Sample Analyzed Compared to Rebound Occurance 
D. Deep Sequencing Phylogenetic TreesA.  Sample and Patient information 
R4
R6
Sample ID PID Nadir CD4 Cell Count 
(categorized)
CD4 at Time of 
Sample
VL of Sample
R 0 43656 201-500 11337
R1 43656 201-500 471 1226
R2 291131 201-500 807 8267
R3 621260 201-500 798 1738
R4 141496 201-500 539 1911
R5 621243 201-500 455 3437
R6 621312 201-500 432 1335
R7 291180 201-500 1000 2525
R8 83111 Data Not Avalible 1287 1317
R9 111899 201-500 578 4691














R0 N/A 5 5
R1 3 3
R2 10 1 2
R3 3 5 5
R4 3 3 3
R5 4 5 4
R6 3 1 1
R7 4 3
R8 2 3 3
R9 1 3 3
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Figure 1: Sample/subject information and phylogenetic analysis of env sequences using a 
deep sequencing approach. 
A. Sample and subject information includes a key for which samples were from which subjects, 
as well as nadir CD4 over the course of subjects care categories where available, CD4 levels at 
the time of sampling, and viral loads.  
B. Comparison of the sample analyzed versus time to viral rebound was recorded. In the majority 
of subjects, we were able to analyze the first sample in which virus was detected or a sample 
very close to rebound detection.  
C. A comparison of the number of the minimum number of major lineages is represented in both 
deep sequencing phylogenetic analysis and SGA phylogenetic analysis.   
D. Phylogenetic trees, created in FigTree, of the sequenced samples produced using deep 
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Figure 2: Phylogenetic analysis of env sequences and tropism determination results.  
A. Phylogenetic tree, created using MEGA, of the sequences of subject 43656 pre-therapy, R0 
(●) sample and rebound sample, R1 (ᴼ) generated using SGA. Cloned and tropism-analyzed env 
sequences are marked with a * beside each label.   
B-D. Tissue culture assay results using pseudotyped virus to define viral entry tropism 
phenotypes  
B. Relative infectivity of pseudoviruses (represented by red bars, while gray bars are controls) 
was determined using Affinofile cells induced to expressing low levels of CD4 compared to 
infection at high levels of CD4. Relative infectivity of all pseudotyped virus was below 2% and 
indicates T cell-tropism.   
C. Relative infectivity of pseudovirus in the presence of CCR5 antagonist Maraviroc 
(represented by red bars while gray bars are controls) showed nearly complete inhibition of all 
pseudotyped viruses and indicates usage of CCR5.   
D. Relative infectivity of TZM-bl cells by pseudotyped virus in the presence of soluble CD4 
(represented by purple bars while gray bars are controls) showed resistance to inhibition by all 











Figure 3: Highlighter plot analysis of env sequences 
Highlighter plots were generated from SGA env sequences using the Los Alamos National 
Laboratory Highlighter generator program. Highlighter plots compare each amplicon sequence to 
a master sequence designated for that patient. Differences between each sequence and the master 
sequence are denoted by colored marks corresponding to the location in which this variation is 
located as well as the nature of the mutation.  
Key: 
























































































































Figure 4: Phylogenetic analysis of env sequences. Phylogenetic trees, created using MEGA, of 
the sequences from all samples (●) sample generated using SGA. Cloned and tropism analyzed 




Figure 5: Phylogenetic analysis of all env sequences.  Phylogenetic tree, created using MEGA, 
of all of the sequences from all samples generated using SGA to test for any contamination. No 
contamination was detected. If it were present, contamination would have been revealed when 
sequences from two or more patients appeared to have identical or near-identical sequences as 
indicated by proximity on this phylogenetic tree.  
  









R1	 43656	 Male	 37	 Chronic	 3.95	 cmbv	efv	 <50	
R2	 291131	 Male	 57	 Chronic	 2.87	 cmbv	efv	 <50	
R3	 621260	 Male	 50	 Chronic	 3.06	 cmbv	efv	 <50	
R4	 141496	 Male	 45	 Chronic	 3.06	 d4t	3tc	kal	 <50	
R5	 621243	 Male	 56	 Chronic	 4.71	 d4t	3tc	efv	 <50	
R6	 621312	 Male	 52	 Chronic	 3.53	 cmbv	efv	 <50	
R7	 291180	 Male	 48	 Chronic	 5.71	 cmbv	efv	 <50	
R8	 83111	 Male	 49	 Chronic	 7.07	 d4t	3tc	idv	rtv	 <50	
R9	 111899	 Male	 48	 Chronic	 8.99	 cmbv	idv	rtv	 <50	
R10	 621388	 Female	 44	 Chronic	 4.68	 3tc	tdf	efv	 <50	
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Figure 6: ACTG Study A5068 Patient Data.  Demographic data, treatment prior to 
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